Erasca, Inc.

Erasca, Inc. announced the successful closing of its previously announced upsized public offering, raising approximately $632.5 million in gross proceeds. The company sold 36,142,857 shares of its common stock at a price of $17.50 per share, which included the full exercise of the underwriters' option to purchase additional shares. Erasca plans to utilize the net proceeds from this offering, combined with its existing cash, to fund the research and development of its product candidates and for general corporate purposes.

Erasca, Inc. announced the pricing of an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, expecting gross proceeds of approximately $550.0 million. The underwriters also have a 30-day option to purchase up to an additional 4,714,285 shares. Net proceeds are anticipated to be around $516.0 million, or $593.5 million if the option is fully exercised, which will be used to fund research and development of product candidates and for general corporate purposes. The offering is slated to close on July 15, 2026.

Erasca, Inc. announced the pricing of an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share. The offering is expected to generate gross proceeds of approximately $550.0 million for the company. Erasca has also granted underwriters an option to purchase up to an additional 4,714,285 shares. The net proceeds from this offering will be used to fund research and development of its product candidates and for general corporate purposes.

Erasca announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015 from the AURORAS-1 trial. The drug demonstrated encouraging monotherapy responses with a 57% uORR8wk in patients with 2L+ KRAS G12X pancreatic ductal adenocarcinoma and continued to be generally well-tolerated. The company also reported promising combination potential with panitumumab and is accelerating its potentially registration-enabling development plans for NSCLC and PDAC, with trials expected to begin in 2027 and early 2028.

Erasca, Inc. announced its intention to offer and sell $500.0 million of shares of its common stock in a proposed underwritten public offering. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of common stock. Proceeds from the offering, combined with existing cash, will be used to fund research and development of its product candidates, other development programs, and for general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.

Erasca, Inc. announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing encouraging monotherapy responses with a 57% unconfirmed Overall Response Rate (uORR) in 2L+ KRAS G12X pancreatic cancer. The drug was generally well-tolerated, and promising combination potential with panitumumab was observed. Based on these results, Erasca plans to accelerate development, initiating a potentially registration-enabling trial in lung cancer in H1 2027, a Phase 3 trial in pancreatic cancer in 2027, and another Phase 3 trial in lung cancer in H2 2027 to H1 2028.

Erasca, Inc. reported a net loss of $183.4 million for Q1 2026, significantly higher than the $31.0 million loss in Q1 2025, primarily due to a $150.0 million in-process research and development expense. This expense was incurred for exercising an option to expand its exclusive license agreement with Joyo Pharmatech to include mainland China, Hong Kong, and Macau for pan-RAS inhibitors. Concurrently, Erasca decided to stop development of its naporafenib program and terminated its license agreement with Novartis Pharma AG. The company also completed an underwritten offering in January 2026, raising $242.7 million in net proceeds.

Erasca, Inc. reported its first quarter 2026 financial results, with a net loss of $183.4 million, or $(0.60) per share, primarily due to a $150 million in-process R&D expense for an expanded license agreement. Despite the increased loss, the company's cash, cash equivalents, and marketable securities stood at a robust $408.5 million, following a successful $258.8 million public offering in January 2026, extending its operational runway into the second half of 2028. The company also provided positive business updates, including robust preliminary monotherapy data for ERAS-0015 and anticipated data for ERAS-4001 in H2 2026, along with new clinical trial collaborations.

Erasca, Inc. reported Q1 2026 financial results and provided business updates, highlighting robust monotherapy efficacy and favorable safety for ERAS-0015 in KRAS G12X NSCLC and PDAC. The company entered into clinical trial collaborations with Merck and Tango Therapeutics for ERAS-0015 combinations and expanded its license agreement for ERAS-0015 to worldwide rights. Erasca also reported a strong cash position of $408.5 million, expected to fund operations into the second half of 2028, following a successful $258.8 million public offering in January 2026. Preliminary data for ERAS-4001 is expected in H2 2026.

Erasca, Inc. announced a clinical trial collaboration and supply agreement with Merck for the AURORAS-1 study. This study will evaluate Erasca's pan-RAS molecular glue ERAS-0015 in combination with Merck's anti-PD-1 therapy KEYTRUDA® for patients with RAS-mutant solid tumors. Erasca will sponsor the study, while Merck will supply pembrolizumab at no cost. The collaboration aims to improve therapeutic benefits and limit treatment resistance in RAS-driven cancers, which affect approximately 2.7 million patients annually worldwide.